

thrombocytopenia · urinary retention · vasculitis · weight decreased

SIDE-EFFECTS, FURTHER INFORMATION The incidence of side-effects is lower if the dose is kept low, but systemic lupus erythematosus should be suspected if there is unexplained weight loss, arthritis, or any other unexplained ill health.

- **PREGNANCY** Neonatal thrombocytopenia reported, but risk should be balanced against risk of uncontrolled maternal hypertension. Manufacturer advises avoid before third trimester.
- **BREAST FEEDING** Present in milk but not known to be harmful.
Monitoring Monitor infant in breast-feeding.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution (risk of accumulation).
Dose adjustments Manufacturer advises adjust dose or dosing interval according to clinical response.
- **RENAL IMPAIRMENT**
Dose adjustments Reduce dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Manufacturer advises test for antinuclear factor and for proteinuria every 6 months and check acetylator status before increasing dose, but evidence of clinical value unsatisfactory.
- **DIRECTIONS FOR ADMINISTRATION**
 - ▶ With oral use For administration *by mouth*, diluted injection may be given orally.
 - ▶ With intravenous use For *continuous intravenous infusion*, initially reconstitute 20 mg with 1 mL Water for Injections, then dilute with Sodium Chloride 0.9%. Incompatible with Glucose intravenous infusion. For *intravenous injection*, initially reconstitute 20 mg with 1 mL Water for Injections, then dilute to a concentration of 0.5–1 mg/mL with Sodium Chloride 0.9% and administer over 5–20 minutes.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

Tablet

EXCIPIENTS: May contain Gluten, propylene glycol

- ▶ **Hydralazine hydrochloride (Non-proprietary)**
Hydralazine hydrochloride 25 mg Hydralazine 25mg tablets | 56 tablet [PoM] £7.37 DT = £5.18 | 84 tablet [PoM] £14.00
Hydralazine hydrochloride 50 mg Hydralazine 50mg tablets | 56 tablet [PoM] £15.46 DT = £7.82
- ▶ **Apresoline** (Advanz Pharma)
Hydralazine hydrochloride 25 mg Apresoline 25mg tablets | 84 tablet [PoM] £3.38

Powder for solution for injection

- ▶ **Hydralazine hydrochloride (Non-proprietary)**
Hydralazine hydrochloride 20 mg Hydralazine 20mg powder for concentrate for solution for injection ampoules | 5 ampoule [PoM] £74.17

Minoxidil

● INDICATIONS AND DOSE

Severe hypertension

▶ BY MOUTH

- ▶ Child 1 month–11 years: Initially 200 micrograms/kg daily in 1–2 divided doses, then increased in steps of 100–200 micrograms/kg, increased at intervals of at least 3 days; maximum 1 mg/kg per day
- ▶ Child 12–17 years: Initially 5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg daily, increased at intervals of at least 3 days, seldom necessary to exceed 50 mg daily; maximum 100 mg per day

- **CONTRA-INDICATIONS** Phaeochromocytoma

- **CAUTIONS** Acute porphyrias p. 624
- **INTERACTIONS** → Appendix 1: minoxidil
- **SIDE-EFFECTS**
 - ▶ **Common or very common** Fluid retention · hair changes · oedema · pericardial disorders · pericarditis · tachycardia
 - ▶ **Rare or very rare** Leucopenia · skin reactions · Stevens-Johnson syndrome · thrombocytopenia
 - ▶ **Frequency not known** Angina pectoris · breast tenderness · gastrointestinal disorder · pleural effusion · sodium retention · weight increased
- **PREGNANCY** Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.
- **BREAST FEEDING** Present in milk but not known to be harmful.
- **RENAL IMPAIRMENT** Use with caution in significant impairment.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

▶ **Loniten** (Pfizer Ltd)

- Minoxidil 2.5 mg** Loniten 2.5mg tablets | 60 tablet [PoM] £8.88 DT = £8.88
- Minoxidil 5 mg** Loniten 5mg tablets | 60 tablet [PoM] £15.83 DT = £15.83
- Minoxidil 10 mg** Loniten 10mg tablets | 60 tablet [PoM] £30.68 DT = £30.68

4.1a Hypertension associated with phaeochromocytoma

Other drugs used for Hypertension associated with phaeochromocytoma Propranolol hydrochloride, p. 106

VASODILATORS > PERIPHERAL VASODILATORS

Phenoxybenzamine hydrochloride

● INDICATIONS AND DOSE

Hypertension in phaeochromocytoma

▶ BY MOUTH

- ▶ Child: 0.5–1 mg/kg twice daily, adjusted according to response

- **UNLICENSED USE** Not licensed for use in children.
- **CONTRA-INDICATIONS** History of cerebrovascular accident
- **CAUTIONS** Avoid contact with skin (risk of contact sensitisation) · avoid in Acute porphyrias p. 624 · carcinogenic in *animals* · cerebrovascular disease · congestive heart failure · severe ischaemic heart disease
- **SIDE-EFFECTS** Abdominal distress · dizziness · ejaculation failure · fatigue · miosis · nasal congestion · postural hypotension · reflex tachycardia
- **PREGNANCY** Hypotension may occur in newborn.
- **BREAST FEEDING** May be present in milk.
- **RENAL IMPAIRMENT** Use with caution.
- **DIRECTIONS FOR ADMINISTRATION** For administration *by mouth*, capsules may be opened.
- **HANDLING AND STORAGE** Owing to risk of contact sensitisation healthcare professionals should avoid contamination of hands.